The Third BHD Symposium will be held this year on 11th and 12th May in Maastricht, the Netherlands. Researchers interested in presenting at the Symposium have just over two weeks to submit their abstracts before the deadline on 15th March. The Symposium welcomes scientists and patients from around the world who are interested in BHD syndrome and HLRCC. We are excited to announce that Professor Ian Tomlinson of the Wellcome Trust Centre for Human Genetics, University of Oxford and Dr Patrick Pollard of the Centre for Cellular and Molecular Physiology, University of Oxford, have agreed to speak at the Symposium. Click here for full details, including information on registration.
Details are also being finalised for the patient and family sessions and registration for this will open soon. BHD doctors and a genetic counsellor will be speaking and leading Q&A sessions. Patients and families are also welcome to attend the researcher sessions.
The aims of the Symposium are to communicate advances in the understanding, management and treatment of BHD syndrome. This year, the Symposium will also focus on hereditary leiomyomatosis and renal cell cancer (HLRCC). HLRCC results from a mutation in the fumarate hydratase (FH) gene. Patients with HLRCC develop skin lesions and have a predisposition to renal cell carcinoma, much like the manifestations seen in BHD syndrome. It will be interesting to further explore and discuss the overlap of these phenotypically similar diseases.
Abstracts for posters can be submitted here. The categories for abstracts are BHD basic science, BHD clinical science, HLRCC basic science and HLRCC clinical science. After the abstract submission deadline, successful authors will be invited to present their work either as an oral presentation or poster. Prizes will be awarded for exceptional posters, so get your abstract in now!
We look forward to seeing you in Maastricht for what promises to be an interesting and insightful conference for all involved in the BHD and HLRCC community.